

Conclusion of Investment Agreement with Japan Hydrogen Fund, L.P.

OSAKA, Japan, July 16, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi has entered into an investment agreement with "Japan Hydrogen Fund, L.P." (hereafter "the Fund"), a fund dedicated to investments in the hydrogen sector. The Fund was established through the collaboration of The Japan Hydrogen Association (hereafter "the JH2A"), Advantage Partners, and Sumitomo Mitsui DS Asset Management.

The Fund is designed to accelerate the realization of a hydrogen-powered society in Japan by investing in technologies and businesses related to hydrogen, an energy source recognized as a promising alternative to fossil fuels. These efforts are strongly supported by the JH2A, its member companies, and the Government of Japan, as part of a broader initiative to achieve carbon neutrality in response to the global challenge of climate change. Through these strategic investments, the Fund aims to help build a resilient hydrogen supply chain and contribute to a sustainable future.

As part of its commitment to contributing to a sustainable society, Shionogi has identified "Protect the environment" as one of its key material issues. Shionogi is actively working toward achieving the medium- to long-term goals outlined in the SHIONOGI Group EHS Action Targets, with fiscal 2035 set as the target year. In response to climate change, Shionogi has set a goal of reducing greenhouse gas (CO₂) emissions by 60% compared to fiscal 2019 levels by fiscal 2035. Through our investment in the Fund, we aim to contribute to the realization of a hydrogen-based society while achieving a high level of balance between business expansion and environmental consideration. In doing so, we will continue to support the sustainable development of both our group and society as a whole.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html